Phase 2 Study of LY4005130 for Severe Alopecia Areata
Summary
The National Institutes of Health has registered a Phase 2 clinical trial (NCT07533006) on ClinicalTrials.gov evaluating LY4005130, an investigational intravenous drug, in adults with severe alopecia areata. The approximately 48-week randomized controlled trial will assess efficacy, tolerability, safety, and pharmacokinetics of LY4005130 versus placebo. This registry entry provides public transparency on the clinical investigation but does not constitute regulatory approval, authorization, or impose compliance obligations.
What changed
The National Institutes of Health registered a new Phase 2 clinical trial (NCT07533006) on ClinicalTrials.gov investigating LY4005130 in adult participants with severe alopecia areata. The study will be conducted as a randomized, placebo-controlled trial to evaluate the efficacy and safety of the investigational drug administered intravenously over approximately 48 weeks.
Pharmaceutical companies, clinical research organizations, and healthcare providers involved in drug development and clinical research should note this trial registration for pipeline tracking and potential participation opportunities. Patients seeking clinical trial options for alopecia areata may reference this registry entry. The registration provides transparency regarding ongoing clinical investigations but does not create regulatory obligations or compliance deadlines.
Archived snapshot
Apr 16, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
Phase 2 NCT07533006 Kind: PHASE2 Apr 16, 2026
Abstract
The purpose of this study is to evaluate how well LY4005130 works in participants with severe alopecia areata (hair loss) when compared with placebo, and how well it's tolerated and what side effects may occur. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
The study drug will be administered intravenously (IV) (into a vein in the arm).
The study will last approximately 48 weeks, including screening.
Conditions: Alopecia Areata
Interventions: LY4005130, Placebo
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.